Human Anti-Aβ IgGs Target Conformational Epitopes on Synthetic Dimer Assemblies and the AD Brain-Derived Peptide

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Welzel, Alfred T ^a   Williams, Angela D ^b   McWilliams Koeppen, Helen P ^b   Acero, Luis ^b   Weber, Alfred ^c   Blinder, Veronika ^d   Mably, Alex ^a,d   Bunk, Sebastian ^c   Hermann, Corinna ^c   Farrell, Michael A ^e   Ehrlich, Hartmut J ^c   Schwarz, Hans P ^c   Walsh, Dominic M ^a,d   Solomon, Alan ^b   O'Nuallain, Brian ^a,b,d  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^c BAXTER BIOSCIENCE   (Austria)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; EPITOPE; IMMUNOGLOBULIN G;

AFFINITY CHROMATOGRAPHY; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; CONTROLLED STUDY; FLOW RATE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MORPHOLOGY; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN PROTEIN INTERACTION;

AGED; AMYLOID BETA-PEPTIDES; BIOPHYSICS; BRAIN; CIRCULAR DICHROISM; DEMENTIA; DIMERIZATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; MICROSCOPY, ELECTRON; MIDDLE AGED; PEPTIDES; PROTEIN CONFORMATION; SODIUM DODECYL SULFATE; THIAZOLES;

EID: 84870262448     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050317     Document Type: Article

References (52)

1. Thies W, Bleiler L, (2011) 2011 Alzheimer's disease facts and figures. Alzheimers Dement 7: 208-244.
2. Goedert M, Spillantini MG, (2006) A century of Alzheimer's disease. Science 314: 777-781.
3. Wilcox KC, Lacor PN, Pitt J, Klein WL, (2011) Abeta oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol 31: 939-948.
4. Benilova I, Karran E, De Strooper B, (2012) The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15: 349-357.
5. Lemere CA, Masliah E, (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6: 108-119.
6. Morgan D, (2011) Immunotherapy for Alzheimer's disease. J Intern Med 269: 54-63.
7. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, et al. (2002) The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 23: 213-231.
8. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, et al. (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A. 106: 12145-12150.
9. Du Y, Dodel R, Hampel H, Buerger K, Lin S, et al. (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57: 801-805.
10. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, et al. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 52: 253-256.
11. O'Nuallain B, Acero L, Williams AD, Koeppen HP, Weber A, et al. (2008) Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 47: 12254-12256.
12. Dodel R, Neff F, Noelker C, Pul R, Du Y, et al. (2010) Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 70: 513-528.
13. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, et al. (2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30: 1728-1736.
14. Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, et al. (2012) Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation 9: 105.
15. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, et al. (2007) Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 27: 233-245.
16. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, et al. (2010) Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 7: 90.
17. O'Nuallain B, Hrncic R, Wall JS, Weiss DT, Solomon A, (2006) Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol 176: 7071-7078.
18. Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, et al. (2011) Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 31: 5847-5854.
19. Szabo P, Relkin N, Weksler ME, (2008) Natural human antibodies to amyloid beta peptide. Autoimmun Rev 7: 415-420.
20. Solomon B, (2007) Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther 9: 79-85.
21. Du Y, Wei X, Dodel R, Sommer N, Hampel H, et al. (2003) Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 126: 1935-1939.
22. Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, et al. (2010) Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 227: 167-174.
23. O'Nuallain B, Wetzel R, (2002) Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A 99: 1485-1490.
24. Town T, Tan J, Sansone N, Obregon D, Klein T, et al. (2001) Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Neurosci Lett 307: 101-104.
25. Shankar GM, Walsh DM, (2009) Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener 4: 48.
26. Walsh DM, Selkoe DJ, (2007) A beta oligomers- a decade of discovery. J Neurochem 101: 1172-1184.
27. Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, et al. (2010) Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 30: 6315-6322.
28. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, et al. (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133: 1328-1341.
29. Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, et al. (1999) Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 38: 14101-14108.
30. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, et al. (2010) Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 30: 14411-14419.
31. Shevchenko A, Wilm M, Vorm O, Mann M, (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858.
32. Levine H, 3rd. (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T methods. Methods Enzymol: 274-284.
33. O'Nuallain B, Klyubin I, Mc Donald JM, Foster JS, Welzel A, et al. (2011) A monoclonal antibody against synthetic Abeta dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Abeta. J Neurochem 119: 189-201.
34. Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM, (2011) Isolation of low-n amyloid beta-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol 670: 33-44.
35. Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, et al. (2008) Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis 31: 442-450.
36. Li Q, Gordon M, Cao C, Ugen KE, Morgan D, (2007) Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci 8: 22.
37. Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, et al. (1999) Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 274: 15990-15995.
38. Shankar GM, Li SM, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
39. Wahlstrom A, Hugonin L, Peralvarez-Marin A, Jarvet J, Graslund A, (2008) Secondary structure conversions of Alzheimer's Abeta(1-40) peptide induced by membrane-mimicking detergents. Febs J 275: 5117-5128.
40. Giacomelli CE, Norde W, (2005) Conformational changes of the amyloid beta-peptide (1-40) adsorbed on solid surfaces. Macromol Biosci 5: 401-407.
41. Gandy S, (2010) Testing the amyloid hypothesis of Alzheimer's disease in vivo. Lancet Neurol 9: 333-335.
42. Golde TE, Das P, Levites Y, (2009) Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol Disord Drug Targets 8: 31-49.
43. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98: 8850-8855.
44. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, et al. (2006) Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J 20: 2576-2578.
45. Seubert P, Barbour R, Khan K, Motter R, Tang P, et al. (2008) Antibody Capture of Soluble Abeta Does Not Reduce Cortical Abeta Amyloidosis in the PDAPP Mouse. Neurodegener Dis 5: 65-71.
46. Weber A, Engelmaier A, Teschner H, Schwarz HP (2009) Gammagard Liquid contains anti-RAGE IGG and SLRP. Alzheimer Dement: P146.
47. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913.
48. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, et al. (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13: 1029-1031.
49. Barlow DJ, Edwards MS, Thornton JM, (1986) Continuous and discontinuous protein antigenic determinants. Nature 322: 747-748.
50. Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA, (2010) Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol 10: 115-119.
51. Avrameas S, Ternynck T, Tsonis IA, Lymberi P, (2007) Naturally occurring B-cell autoreactivity: a critical overview. J Autoimmun 29: 213-218.
52. O'Nuallain B, Williams A, McWilliams Koeppen HP, Acero L, Weber A, et al. (2010) Anti-amyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol 30Suppl 1: S37-42.